This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.
DaVita HealthCare (DVA) Registers a Bigger Fall Than the Market: Important Facts to Note
by Zacks Equity Research
DaVita HealthCare (DVA) closed the most recent trading day at $140.37, moving 2.91% from the previous trading session.
Can Phosphate Binders Drive DaVita Stock Before Q2 Earnings?
by Zacks Equity Research
DVA rides early momentum from phosphate binders ahead of second-quarter 2025 earnings, but PD supply issues may cloud growth.
Chemed (CHE) Q2 Earnings Miss Estimates
by Zacks Equity Research
Chemed (CHE) delivered earnings and revenue surprises of -10.67% and +0.45%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
DaVita HealthCare (DVA) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
DaVita HealthCare (DVA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Universal Health to Report Q2 Earnings: What Do the Key Estimates Say?
by Zacks Equity Research
UHS' Q2 results are likely to reflect gains from hospital and behavioral health services. However, rising costs may cloud earnings upside.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Quest Diagnostics (DGX) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Quest Diagnostics (DGX) delivered earnings and revenue surprises of +1.95% and +1.54%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
DaVita HealthCare (DVA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
DaVita HealthCare (DVA) reached $139.43 at the closing of the latest trading day, reflecting a -1.23% change compared to its last close.
Will DaVita HealthCare (DVA) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
DaVita HealthCare (DVA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
HCA Healthcare to Report Q2 Earnings: Key Estimates to Note
by Zacks Equity Research
The Zacks Consensus Estimate for HCA's Q2 EPS and revenues suggests a year-over-year upside despite higher costs and surgery volume pressure.
DaVita HealthCare (DVA) Dips More Than Broader Market: What You Should Know
by Zacks Equity Research
In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $140.53, denoting a -2.01% move from the preceding trading day.
Here's Why DaVita HealthCare (DVA) is a Strong Momentum Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
DaVita HealthCare (DVA) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
DaVita HealthCare (DVA) concluded the recent trading session at $141.84, signifying a -1.36% move from its prior day's close.
Zacks Industry Outlook Highlights Quest Diagnostics, Encompass Health, DaVita and The Pennant
by Zacks Equity Research
DGX, EHC, DVA, and PNTG are riding the outpatient healthcare shift as tech, AI, and aging demand reshape the care landscape.
4 Stocks to Watch in a Rapidly Shifting Outpatient Home Health Space
by Debanjana Dey
An aging global population and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry despite the macroeconomic challenges. DGX, EHC, DVA and PNTG are well-poised to gain.
Why DaVita HealthCare (DVA) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
DaVita HealthCare (DVA) Rises As Market Takes a Dip: Key Facts
by Zacks Equity Research
In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $146.71, denoting a +2.99% move from the preceding trading day.
FMS Stock Likely to Gain on New Optimization Plan FME Reignite
by Zacks Equity Research
Fresenius Medical Care unveils FME Reignite, targeting one billion euros in cost savings, tech upgrades and enhanced shareholder returns.
DaVita HealthCare (DVA) Outperforms Broader Market: What You Need to Know
by Zacks Equity Research
DaVita HealthCare (DVA) reached $137.84 at the closing of the latest trading day, reflecting a +1.26% change compared to its last close.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
DaVita HealthCare (DVA) Down 3.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why DaVita HealthCare (DVA) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why DaVita HealthCare (DVA) is a Strong Growth Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why DaVita HealthCare (DVA) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.